Fewer systematic prostate core biopsies in clinical stage T1c prostate cancer leads to biochemical recurrence after brachytherapy as monotherapy

Author:

Ozawa Yu1ORCID,Nohara Sunao1,Nakamura Ken1,Hattori Seiya1,Yagi Yasuto1,Nishiyama Toru1,Yorozu Atsunori2,Monma Tetsuo1,Saito Shiro3

Affiliation:

1. Department of Urology National Hospital Organization Tokyo Medical Center Tokyo Japan

2. Department of Radiation Oncology National Hospital Organization Tokyo Medical Center Tokyo Japan

3. Department of Urology Prostate Cancer Center Ofuna Chuo Hospital Kanagawa Japan

Abstract

AbstractBackgroundAfter brachytherapy, fewer prostate biopsy cores at diagnosis can underestimate the pathological characteristics of prostate cancer (PCa) with lower concordance, resulting in improper treatment, particularly in patients with low‐risk nonpalpable cT1c PCa. The aim of this study was to assess the relationship between the number of biopsy cores at diagnosis and long‐term clinical outcomes after brachytherapy for cT1c PCa.MethodsWe reviewed 516 patients with localized cT1c PCa with Gleason scores of 3 + 3 = 6 or 3 + 4 = 7 who underwent brachytherapy as monotherapy without hormonal therapy between January 2005 and September 2014 at our institution. Clinical staging was based on the American Joint Committee on Cancer manual for staging. Thus, the cT1c category is based solely on digital rectal examination. The primary outcome was biochemical recurrence (BCR). Based on the optimized cutoff value for biopsy core number obtained from receiver operating characteristic analysis, patients were divided into the biopsy cores ≤8 (N = 123) and ≥9 (N = 393) groups. The BCR‐free survival rate was compared between the groups. Prognostic factors for BCR were evaluated, including age, initial prostate‐specific antigen (PSA) level, Gleason score, positive core rate, PSA density, prostate magnetic resonance imaging findings, and biopsy core number.ResultsThe median patient age was 66.0 years (interquartile range [IQR]: 61.0–71.0 years), and the median follow‐up time was 11.1 years (IQR: 9.5–13.3 years). The median number of core biopsies was 12 (IQR: 9–12). The area under the curve was 0.637 (95% confidence interval [CI]: 0.53–0.75), and the optimal biopsy core cutoff value for BCR prediction was 8.5 (sensitivity = 43.5%, specificity = 77.1%). Although fewer patients had Gleason scores of 3 + 4 = 7 (19/123 [15%] vs. 125/393 [32%], p < 0.02) in the biopsy cores ≤8 group, the 10‐year BCR‐free survival rate was significantly lower in the biopsy cores ≤8 group than in the biopsy cores ≥9 group (93.8% vs. 96.3%, p < 0.05). Multivariate analysis revealed that a lower biopsy core number (hazard ratio: 0.828, 95% CI: 0.71–0.97, p < 0.03) and a Gleason score of 3 + 4 = 7 (hazard ratio: 3.26, 95% CI: 1.37–7.73, p < 0.01) significantly predicted BCR.ConclusionsA low number of prostate core biopsies results in worse BCR‐free survival after brachytherapy as monotherapy in patients with cT1c PCa.

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3